Fact CheckerSign in

NCT07212075Recruiting

Precision Subclassification of Mental Health in Diabetes: Digital Twins for Precision Mental Health to Track Subgroups

Source: ClinicalTrials.gov · Last updated 4 Dec 2025

Brief summary (registry, in English)

Mental conditions and disorders (e.g. distress, depressive, anxiety, and eating disorders) are more prevalent in people with diabetes (PWD) and associated with reduced quality of life and impaired glycaemic outcomes. Evidence supports a complex network between psychosocial factors and glycaemic control that can be highly variable between persons. It is assumed that subgroups exist that show different trajectories of glycaemia and mental health. Belonging to a particular subgroup may be linked with a higher risk of developing mental health problems compared to others. This suggests that it is possible to treat individuals in different subgroups in a manner that optimizes their treatment and can improve health outcomes. Accurate characterisation can inform more individualized care. This calls for a more personalised approach considering the idiosyncrasies of different subgroups. Over 3 years, the investigators have established the basis of a precision mental health approach for diabetes using n-of-1 analyses. By utilizing combined ecological momentary assessment (EMA: repeated daily sampling of psychosocial factors in everyday life) and continuous glucose monitoring (CGM), intensive longitudinal data per person could be collected. This enables the analysis of individual associations between glycaemic parameters and psychosocial variables and identification of individual sources of diabetes distress in each person. The objective of the present study is to use of the n-of-1 approach to identify subgroups of PWD who share common characteristics in the associations between glucose and psychosocial variables. The identified subgroups shall be used to develop a digital twin for precision mental health in diabetes. The digital twin serves as representation of a real person, allowing to make simulations and predictions of the course of mental health and glycaemia. These predictions can inform diabetes care and lead to more precise, personalised treatment decisions. To achieve this, a longitudinal panel including over 1,400 PWD who continuously complete EMA and questionnaire surveys and measure glucose levels using CGM was developed. Over 1000 clinical interviews to diagnose mental disorders have been conducted to identify major mental health conditions and map mental outcomes. To identify subgroups and develop the digital twin, the sampling will be expanded aiming at a total of 1,809 PWD. Incidence and remission of mental disorders will be determined via repeated interviews. The complex networks between clinical, metabolic, and psychosocial data will be analysed using machine learning, leading to new insights with the potential to shape future guidelines. These results will be used by the digital twin to predict courses of glycaemic control and mental health, translating the individual evidence into direct treatment suggestions.

Status (registry)
Recruiting
Study type
Observational
Enrollment
1809 (estimated)
First submitted
1 Oct 2025
Start date
1 Jan 2025
Primary completion date
31 Aug 2027
Lead sponsor
Forschungsinstitut der Diabetes Akademie Mergentheim
NCT number
NCT07212075

What you commit to

  • Study type: Observational
  • Planned participants: 1809
  • From 1 Jan 2025 to the primary completion date, 31 Aug 2027
  • 3 sites in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Other illness

  • Significant cognitive impairment (e.g. dementia)
  • Severe disorder or condition impacting the person's ability to participate in the study or likely to confound results (e.g. treated cancer, heart disease ≥ NYHA III, schizophrenia/psychotic disorder)
  • Terminal illness

Other

  • Inability to consent
  • Being bedridden

Who the study is looking for

  • 18 to 80 years of age
  • Diagnosis of type 1 diabetes or type 2 diabetes or other specific type of diabetes
  • Diabetes duration ≥ 1 year
  • Sufficient German language skills
  • Informed consent

Age in the registry: 18 years to 80 years · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (3)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
MVZ Diabetespraxis Mergentheim
Coordinator of this site? Confirm its status
Bad MergentheimGermanyCompleted
Diabetes Clinic Mergentheim (DCM)
Coordinator of this site? Confirm its status
Bad MergentheimGermanyRecruiting
MVZ DiaMedicum Würzburg
Coordinator of this site? Confirm its status
WürzburgGermanyCompleted

This page is information, not medical advice. Discuss any trial with your doctor.